News

Imaging Endpoints Assists FORMA Therapeutics as Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma. The Data Was Recently Presented at the 2019 Society for NeuroOncology Annual Meeting. WATERTOWN, Mass. –…   Read More

Imaging Endpoints is perhaps the fastest-growing imaging CRO (iCRO) in the industry. We are proud to celebrate our tenth consecutive year of impressive growth and contribution to our mission of Connecting Imaging to the CureTM. Client retention and leadership in…   Read More

Key Points Question Is adding cisplatin to nab-paclitaxel and gemcitabine treatment associated with increased overall survival and complete response potential among patients with metastatic pancreatic adenocarcinoma? Findings In this single-arm, phase 1b/2 clinical trial of 25 patients, the combination of…   Read More

TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomes SM-88 is an oral, investigational cancer metabolism-based therapy that has demonstrated confirmed clinical responses…   Read More

SCOTTSDALE, Ariz., Sept. 12, 2019, /PRNewswire/ -- Imaging Endpoints (IE) has announced the opening of its new corporate headquarters in Scottsdale, Arizona to accommodate the company's tremendous growth. The company also has an office in Waltham, Massachusetts as well as…   Read More

Summary Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ~50% of metastatic MM patients developing brain metastases (BM). Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM. However, responses…   Read More

Archival tumor samples represent a rich resource of annotated specimens for translational genomics research. However, standard variant calling approaches require a matched normal sample from the same individual, which is often not available in the retrospective setting, making it difficult…   Read More

Abstract Pancreas cancer is an aggressive and fatal disease that will become one of the leading causes of cancer mortality by 2030. An all-out effort is underway to better understand the basic biologic mechanisms of this disease ranging from early…   Read More

Abstract Background. Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP‐ribose) polymerase (PARP) inhibitor olaparib. We performed a single-institution…   Read More